E
Allogene Therapeutics, Inc.
ALLO
$1.45
$0.085.84%
E
Sell
3/17/2025Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 3/17/2025 due to a decline in the total return index, volatility index and valuation index.
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 3/17/2025 due to a decline in the total return index, volatility index and valuation index.
D
Sell
2/7/2025Upgraded
Allogene Therapeutics, Inc. (ALLO) was upgraded to D- from E+ on 2/7/2025 due to an increase in the growth index, volatility index and valuation index.
Allogene Therapeutics, Inc. (ALLO) was upgraded to D- from E+ on 2/7/2025 due to an increase in the growth index, volatility index and valuation index.
E
Sell
1/23/2025Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 1/23/2025 due to a decline in the total return index and volatility index.
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 1/23/2025 due to a decline in the total return index and volatility index.
D
Sell
1/8/2025Upgraded
Allogene Therapeutics, Inc. (ALLO) was upgraded to D- from E+ on 1/8/2025 due to an increase in the total return index and volatility index.
Allogene Therapeutics, Inc. (ALLO) was upgraded to D- from E+ on 1/8/2025 due to an increase in the total return index and volatility index.
E
Sell
12/20/2024Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 12/20/2024 due to a decline in the volatility index.
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 12/20/2024 due to a decline in the volatility index.
D
Sell
7/17/2024Upgraded
Allogene Therapeutics, Inc. (ALLO) was upgraded to D- from E+ on 7/17/2024 due to an increase in the volatility index.
Allogene Therapeutics, Inc. (ALLO) was upgraded to D- from E+ on 7/17/2024 due to an increase in the volatility index.
E
Sell
7/2/2024Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 7/2/2024 due to a decline in the total return index and volatility index.
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 7/2/2024 due to a decline in the total return index and volatility index.
D
Sell
6/17/2024Upgraded
Allogene Therapeutics, Inc. (ALLO) was upgraded to D- from E+ on 6/17/2024 due to an increase in the volatility index.
Allogene Therapeutics, Inc. (ALLO) was upgraded to D- from E+ on 6/17/2024 due to an increase in the volatility index.
E
Sell
5/31/2024Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 5/31/2024 due to a decline in the volatility index and total return index.
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 5/31/2024 due to a decline in the volatility index and total return index.
D
Sell
5/14/2024Upgraded
Allogene Therapeutics, Inc. (ALLO) was upgraded to D- from E+ on 5/14/2024 due to a noticeable increase in the growth index, volatility index and solvency index. Total revenue increased 150% from -$44 to $22, earnings per share increased from -$0.5302 to -$0.3843, and EBIT increased 3.37% from -$71.93M to -$69.5M.
Allogene Therapeutics, Inc. (ALLO) was upgraded to D- from E+ on 5/14/2024 due to a noticeable increase in the growth index, volatility index and solvency index. Total revenue increased 150% from -$44 to $22, earnings per share increased from -$0.5302 to -$0.3843, and EBIT increased 3.37% from -$71.93M to -$69.5M.
E
Sell
5/9/2024Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 5/9/2024 due to a decline in the volatility index, total return index and growth index.
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 5/9/2024 due to a decline in the volatility index, total return index and growth index.
D
Sell
4/19/2024Upgraded
Allogene Therapeutics, Inc. (ALLO) was upgraded to D- from E+ on 4/19/2024 due to an increase in the volatility index and solvency index.
Allogene Therapeutics, Inc. (ALLO) was upgraded to D- from E+ on 4/19/2024 due to an increase in the volatility index and solvency index.
E
Sell
4/4/2024Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 4/4/2024 due to a decline in the volatility index and solvency index.
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 4/4/2024 due to a decline in the volatility index and solvency index.
D
Sell
3/18/2024Upgraded
Allogene Therapeutics, Inc. (ALLO) was upgraded to D- from E+ on 3/18/2024 due to an increase in the volatility index and total return index.
Allogene Therapeutics, Inc. (ALLO) was upgraded to D- from E+ on 3/18/2024 due to an increase in the volatility index and total return index.
E
Sell
3/13/2024Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 3/13/2024 due to a decline in the volatility index.
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 3/13/2024 due to a decline in the volatility index.
D
Sell
2/27/2024Upgraded
Allogene Therapeutics, Inc. (ALLO) was upgraded to D- from E+ on 2/27/2024 due to a large increase in the growth index, volatility index and efficiency index. Earnings per share increased from -$0.5313 to -$0.3657, EBIT increased 21.79% from -$80.52M to -$62.98M, and net income increased 21.38% from -$77.99M to -$61.32M.
Allogene Therapeutics, Inc. (ALLO) was upgraded to D- from E+ on 2/27/2024 due to a large increase in the growth index, volatility index and efficiency index. Earnings per share increased from -$0.5313 to -$0.3657, EBIT increased 21.79% from -$80.52M to -$62.98M, and net income increased 21.38% from -$77.99M to -$61.32M.
E
Sell
3/1/2023Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 3/1/2023 due to a noticeable decline in the solvency index, total return index and volatility index. The quick ratio declined from 11.42 to 9.55.
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 3/1/2023 due to a noticeable decline in the solvency index, total return index and volatility index. The quick ratio declined from 11.42 to 9.55.
D
Sell
11/4/2022Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to D- from D on 11/4/2022 due to a large decline in the growth index and solvency index. Total revenue declined 43.02% from $86 to $49, operating cash flow declined 12.05% from -$42.53M to -$47.66M, and earnings per share declined from -$0.5216 to -$0.5788.
Allogene Therapeutics, Inc. (ALLO) was downgraded to D- from D on 11/4/2022 due to a large decline in the growth index and solvency index. Total revenue declined 43.02% from $86 to $49, operating cash flow declined 12.05% from -$42.53M to -$47.66M, and earnings per share declined from -$0.5216 to -$0.5788.
D
Sell
8/3/2022Upgraded
Allogene Therapeutics, Inc. (ALLO) was upgraded to D from D- on 8/3/2022 due to an increase in the total return index and volatility index.
Allogene Therapeutics, Inc. (ALLO) was upgraded to D from D- on 8/3/2022 due to an increase in the total return index and volatility index.
D
Sell
7/19/2022Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to D- from D on 7/19/2022 due to a decline in the volatility index.
Allogene Therapeutics, Inc. (ALLO) was downgraded to D- from D on 7/19/2022 due to a decline in the volatility index.
D
Sell
7/1/2022Upgraded
Allogene Therapeutics, Inc. (ALLO) was upgraded to D from D- on 7/1/2022 due to an increase in the volatility index and total return index.
Allogene Therapeutics, Inc. (ALLO) was upgraded to D from D- on 7/1/2022 due to an increase in the volatility index and total return index.
D
Sell
5/31/2022Upgraded
Allogene Therapeutics, Inc. (ALLO) was upgraded to D- from E+ on 05/31/2022.
Allogene Therapeutics, Inc. (ALLO) was upgraded to D- from E+ on 05/31/2022.
E
Sell
5/13/2022Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 5/13/2022 due to a decline in the total return index.
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 5/13/2022 due to a decline in the total return index.
D
Sell
5/9/2022Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to D- from D on 5/9/2022 due to a noticeable decline in the growth index, solvency index and volatility index. Operating cash flow declined 50.18% from -$45.44M to -$68.24M, EBIT declined 8.25% from -$73.89M to -$79.99M, and earnings per share declined from -$0.5379 to -$0.5649.
Allogene Therapeutics, Inc. (ALLO) was downgraded to D- from D on 5/9/2022 due to a noticeable decline in the growth index, solvency index and volatility index. Operating cash flow declined 50.18% from -$45.44M to -$68.24M, EBIT declined 8.25% from -$73.89M to -$79.99M, and earnings per share declined from -$0.5379 to -$0.5649.
D
Sell
5/4/2022Upgraded
Allogene Therapeutics, Inc. (ALLO) was upgraded to D from E+ on 05/04/2022.
Allogene Therapeutics, Inc. (ALLO) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index.
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index.
D
Sell
4/21/2022Upgraded
Allogene Therapeutics, Inc. (ALLO) was upgraded to D from E+ on 04/21/2022.
Allogene Therapeutics, Inc. (ALLO) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index and volatility index.
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index and volatility index.
D
Sell
2/28/2022Upgraded
Allogene Therapeutics, Inc. (ALLO) was upgraded to D from D- on 2/28/2022 due to a noticeable increase in the growth index and valuation index. Operating cash flow increased 7.04% from -$48.88M to -$45.44M, earnings per share increased from -$0.5706 to -$0.5379, and EBIT increased 4.86% from -$77.67M to -$73.89M.
Allogene Therapeutics, Inc. (ALLO) was upgraded to D from D- on 2/28/2022 due to a noticeable increase in the growth index and valuation index. Operating cash flow increased 7.04% from -$48.88M to -$45.44M, earnings per share increased from -$0.5706 to -$0.5379, and EBIT increased 4.86% from -$77.67M to -$73.89M.
D
Sell
2/24/2022Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to D- from D on 2/24/2022 due to a decline in the total return index and volatility index.
Allogene Therapeutics, Inc. (ALLO) was downgraded to D- from D on 2/24/2022 due to a decline in the total return index and volatility index.
D
Sell
2/9/2022Upgraded
Allogene Therapeutics, Inc. (ALLO) was upgraded to D from D- on 2/9/2022 due to an increase in the volatility index and valuation index.
Allogene Therapeutics, Inc. (ALLO) was upgraded to D from D- on 2/9/2022 due to an increase in the volatility index and valuation index.
D
Sell
1/25/2022Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to D- from D on 1/25/2022 due to a decline in the total return index and volatility index.
Allogene Therapeutics, Inc. (ALLO) was downgraded to D- from D on 1/25/2022 due to a decline in the total return index and volatility index.
D
Sell
11/9/2021Upgraded
Allogene Therapeutics, Inc. (ALLO) was upgraded to D from E+ on 11/09/2021.
Allogene Therapeutics, Inc. (ALLO) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 12.87 to 9.21.
Allogene Therapeutics, Inc. (ALLO) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 12.87 to 9.21.
D
Sell
10/11/2021Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to D- from D on 10/11/2021 due to a large decline in the growth index, total return index and volatility index. EBIT declined 113.94% from -$33.2M to -$71.03M, earnings per share declined from -$0.2498 to -$0.5261, and total revenue declined 99.89% from $38.35M to $44.
Allogene Therapeutics, Inc. (ALLO) was downgraded to D- from D on 10/11/2021 due to a large decline in the growth index, total return index and volatility index. EBIT declined 113.94% from -$33.2M to -$71.03M, earnings per share declined from -$0.2498 to -$0.5261, and total revenue declined 99.89% from $38.35M to $44.
D
Sell
7/12/2021Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to D from D+ on 7/12/2021 due to a decline in the total return index and volatility index.
Allogene Therapeutics, Inc. (ALLO) was downgraded to D from D+ on 7/12/2021 due to a decline in the total return index and volatility index.
D
Sell
5/17/2021Upgraded
Allogene Therapeutics, Inc. (ALLO) was upgraded to D+ from D on 5/17/2021 due to a large increase in the solvency index, growth index and total return index. Earnings per share increased from -$0.5281 to -$0.2498, EBIT increased 52.13% from -$69.36M to -$33.2M, and the quick ratio increased from 8.85 to 12.84.
Allogene Therapeutics, Inc. (ALLO) was upgraded to D+ from D on 5/17/2021 due to a large increase in the solvency index, growth index and total return index. Earnings per share increased from -$0.5281 to -$0.2498, EBIT increased 52.13% from -$69.36M to -$33.2M, and the quick ratio increased from 8.85 to 12.84.
D
Sell
3/12/2019Downgrade
Allogene Therapeutics, Inc. (ALLO) was downgraded to D from D+ on 3/12/2019 due to a decline in the valuation index and growth index. EBIT declined 48.94% from -$22.19M to -$33.05M, and operating cash flow declined 25.4% from -$17.13M to -$21.48M.
Allogene Therapeutics, Inc. (ALLO) was downgraded to D from D+ on 3/12/2019 due to a decline in the valuation index and growth index. EBIT declined 48.94% from -$22.19M to -$33.05M, and operating cash flow declined 25.4% from -$17.13M to -$21.48M.
D
Sell
1/11/2019Upgraded
Allogene Therapeutics, Inc. (ALLO) was upgraded to D+ from D on 1/11/2019 due to a large increase in the total return index.
Allogene Therapeutics, Inc. (ALLO) was upgraded to D+ from D on 1/11/2019 due to a large increase in the total return index.
D
Sell
1/8/2019None
Allogene Therapeutics, Inc. (ALLO) was downgraded to D from U on 01/08/2019.
Allogene Therapeutics, Inc. (ALLO) was downgraded to D from U on 01/08/2019.
NASDAQ
04/11/2025 4:00PM Eastern
Quotes delayed
